PinPoint Data Science will be attending WHX Dubai 2026 as part of the UK Pavilion this year. This marks an important milestone in their continued plans to explore international markets and showcase their AI-enabled cancer testing technology to a global healthcare audience.
Developed with the NHS in England, the PinPoint Test is an AI–powered multi-cancer blood test designed to support early diagnosis and reduce systemic pressures on healthcare systems. The technology has been validated in a 5-year real-world evaluation and reflects the growing role of data-driven tools in improving clinical decision-making, optimising diagnostic pathways, and supporting more efficient use of healthcare resources.
PinPoint’s unique approach combines advanced machine-learning techniques with routinely collected blood biomarkers to produce clinically meaningful risk assessments. Rather than replacing clinicians, the PinPoint Test is designed to act as a diagnostic aid, helping healthcare professionals prioritise patients more effectively and reduce unnecessary downstream testing.
At WHX Dubai 2026, PinPoint Data Science aims to explore commercial growth opportunities across the Middle East and beyond. They are particularly keen to engage with organisations interested in collaborative pilot studies, co-development opportunities, and long-term partnerships that support regional adoption.
PinPoint Executive Chair, Dr Nigel Sansom, says: “We’re really excited to be attending WHX Dubai this year. It’s a rare opportunity for an innovator like PinPoint to meet face-to-face with decision makers and people on the frontlines of healthcare delivery in a whole range of international markets.
We’re here to promote something new – machine learning as an upgrade to blood testing, a cost-effective tool for managing cancer risk more effectively without exploding budgets; a product that grows and adapts with you as the needs of your healthcare service change. These are the challenges of the 21st century and we’re keen to work with partners in any region to deliver custom solutions.”
PinPoint is designed for public and private healthcare systems but is also looking to expand into the health check and insurance industries, where risk management is mission critical.
By connecting with partners who share a commitment to evidence-based innovation and patient-centred care, PinPoint aims to accelerate the delivery of AI-enabled cancer testing to healthcare systems worldwide.
For more information, visit www.pinpointdatascience.com or speak to Dr Nigel Sansom at the PinPoint stand on the WHX Dubai 2026 UK Pavillion.
